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ABSTRACT
Objective: In patients with advanced stage epithelial ovarian cancer (EOC) the volume of 
residual tumor after debulking is known as prognostic factor for survival. We wanted to 
examine the relationship between postoperative decline in serum CA125 and residual disease 
after cytoreductive surgery and evaluate perioperative changes in serum CA125 levels as 
predictor for disease-specific survival.
Methods: A retrospective study was conducted of patients with FIGO stage IIb-IV EOC 
treated with cytoreductive surgery, followed by chemotherapy between 1996 and 2010 in 
three hospitals in the Southeastern region of the Netherlands. Data were analyzed with the 
use of multilevel linear regression and Cox-proportional hazard regression models.
Results: A postoperative decline in serum CA125 level of ≥80% was associated with complete 
primary cytoreduction (p=0.035). Univariate analyses showed favorable associations with 
survival for both the degree of decline in serum CA125 and residual tumor after primary 
cytoreduction. In multivariate analyses the decline in serum CA125 but not the outcome of 
surgery remained significantly associated with better survival (HR50%–79%=0.52 [95% CI: 0.28–
0.96] and HR≥80%=0.26 [95% CI: 0.13–0.54] vs. the serum CA125 decline of <50% [p<0.001]).
Conclusion: The current study, although hampered by possible biases, suggests that the 
perioperative decline in serum CA125 is an early biomarker that predicts disease-specific 
survival in patients who underwent primary cytoreductive surgery for advanced stage EOC. If 
confirmed prospectively, the perioperative change in serum CA125 could be a better marker 
for residual tumor volume after primary cytoreductive surgery (and therewith disease-specific 
survival) than the surgeons’ estimation of residual tumor volume.
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Perioperative changes in serum CA125 
levels: a prognostic factor for disease-
specific survival in patients with 
ovarian cancer
INTRODUCTION
Approximately 75% of patients diagnosed with epithelial ovarian cancer have advanced 
stage disease (International Federation of Gynecology and Obstetrics [FIGO] IIb-IV) [1], 
resulting in 5-year survival rates of just 17%–36% [2]. Management of advanced stage ovarian 
cancer consists of surgical cytoreduction and postoperative chemotherapy or neoadjuvant 
chemotherapy and interval debulking.
Serial measurements of cancer antigen 125 (CA125) are routinely used to monitor tumor 
response during chemotherapy, survival being correlated with CA125 decline [3]. In surgery 
the volume of the residual tumor after debulking is known as the most important prognostic 
factor for survival [4,5]. However, the definition of residual disease is subjective, as any 
estimate of residual tumor volume is based on the surgeons’ intraoperative assessment. 
Two studies exploring the clinical significance of changes in serum CA125 levels during 
the perioperative period report that a reduction of ≥80% immediately after surgery is an 
independent prognostic factor for progression-free survival (PFS) [6,7]. However, studies 
examining the correlation between the change in perioperative serum CA125 levels and the 
extent of disease after surgery report conflicting results [8-11].
The objectives of the present study were to investigate the relationship between the postoperative 
decline in serum CA125 levels and the residual tumor volume after primary cytoreductive 
surgery in patients with advanced stage epithelial ovarian cancer, and to determine the value of 
perioperative changes in CA125 levels for predicting disease-specific survival.
MATERIALS AND METHODS
1. Study design and sample selection
The medical records of patients with advanced stage (FIGO IIb-IV) epithelial ovarian cancer 
who were treated with primary cytoreductive surgery followed by adjuvant platinum-taxane 
based chemotherapy at two university hospitals and one regional teaching hospital in the 
Southeastern region of the Netherlands between the 1st January, 1996 and the 31st December, 
2009, were retrospectively reviewed. Primary debulking surgery was the treatment of choice 
for patients with advanced stage ovarian cancer. Only when it was estimated that complete 
or at least optimal (≤1 cm) tumor resection could not be accomplished based on imaging and 
patient’s performance status, treatment with neoadjuvant chemotherapy followed by interval 
debulking surgery was chosen. In this study, patients treated with neoadjuvant chemotherapy 
were excluded. Patients were included if the pre- and postoperative serum CA125 levels were 
documented and assessed within five weeks up to primary cytoreductive surgery, five weeks 
postoperatively and before the initiation of adjuvant chemotherapy. Patients were excluded if 
no data were available regarding pre- and/or postoperative CA125 levels or surgery outcome, 
or if their preoperative CA125 value was within the normal range (≤35 U/mL).
2. Data collection
The following demographic and clinical data were retrieved from individual medical records 
and stored in a database: patient and tumor characteristics at primary diagnosis (age, tumor 
histology and grade, FIGO stage); specified data of the primary surgery (intra-operative volume 
of ascites, extensiveness of surgery, residual disease after primary surgery as documented by the 
surgeon); pre- and postoperative serum CA125 level; type of chemotherapy; and follow-up data.
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3. Definitions
1) Perioperative changes in CA125 levels
Perioperative changes in serum CA125 levels were calculated as the absolute difference 
between pre- and postoperative values. To determine the effect of surgery on serum CA125 
levels, pre- and postoperative measurements were performed as close to the date of surgery 
as possible and before the initiation of adjuvant chemotherapy. If more than one serum 
CA125 level was documented before surgery, the value closest to the date of surgery was used 
for analyses. When more than one postoperative CA125 value was retrieved from the records 
(which was the case for 17 patients), the value obtained immediately before the initiation of 
adjuvant chemotherapy was used. In addition, the percentage reduction in the serum CA125 
level was calculated for each patient. In line with previous studies [7], the study population 
was then categorized into three groups based on changes in serum CA125 levels: ≥80% 
reduction; 50%–79% reduction; and <50% reduction. Ten patients in whom the serum CA125 
level increased postoperatively were included in the latter category.
2) Outcome of cytoreductive surgery
Patients were categorized into three groups according to the presence of residual tumor 
after primary cytoreduction: complete (no macroscopic evidence of residual tumor); 
optimal (residual tumor nodule(s), largest diameter ≤1 cm); and incomplete (residual tumor 
nodule(s), largest diameter >1 cm) [4,5]. Surgery was defined extensive when bowel, upper-
abdominal or, diaphragm resection has been performed.
3) Follow-up
To calculate disease-specific survival, the follow-up time in months was calculated for each 
patient as follows: the time from the date of primary cytoreductive surgery to the time of 
cancer-related death (event cases), or the time of the last recorded follow-up visit or death 
from other cause (censored observations), whichever occurred first.
4. Statistical analysis
Continuous variables were expressed as the mean (IQR, inter quartile range) if normally 
distributed, or as the geometric mean (CI, confidence interval) if skewed. Categorical data 
were expressed as percentages. Variables showing a positive skewed distribution (i.e., pre- 
and postoperative CA125 levels and perioperative reductions in CA125 levels) were loge-
transformed prior to further analyses. Multilevel analyses were undertaken to account for 
differences in survival and CA125 measurements between the three hospitals.
Multilevel linear regression models were used to compare pre- and postoperative and 
absolute reductions in CA125 levels across the three categories of surgical outcome. 
Calculations were first performed without adjustment and then again with adjustment for 
potential confounding factors (age, time between preoperative assessment of CA125 levels 
and surgery, and time between surgery and postoperative measurement of CA125 levels). 
A two-level model was used, with random intercepts at the patient and hospital levels, to 
account for the structure of the data. The chi-squared test was used to compare relative 
reductions in CA125 levels according to the three categories outlined above (≥80%, 50%–79% 
and <50% reductions).
Survival estimates for patients showing different levels of CA125 decline were constructed 
using the Kaplan-Meier method and the data analyzed using the log-rank test. Univariate 
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and multivariate Cox-proportional hazard regression models were used to examine the effects 
of each potential determinant of CA125 levels. The following variables were included in the 
different models: percentage reduction in CA125 levels; age at the time of surgery; histology 
results; tumor grade; FIGO stage; volume of ascites; extent of surgery; and the presence of 
residual disease after primary surgery. The level of CA125 decline was entered into the above 
models either as a continuous variable or as a percentage relative to the three categories 
mentioned above, with a <50% reduction used as the reference level. Graphical examination 
and testing using Schoenfeld’s residuals confirmed that the proportional hazards assumption 
of the models had not been violated. In addition, graphical examinations and the use of partial 
Martingale’s residuals revealed no departure from linearity in the case of continuous variables.
All statistical analyses were performed using the Stata software package, version 13.0 
(StataCorp, College Station, TX, USA) and statistical significance was set at p<0.05.
RESULTS
We identified 498 patients with epithelial ovarian cancer. Based on the in- and exclusion 
criteria, finally 123 patients were enrolled in the study (see flowchart, Fig. 1). The 
characteristics of both patients included and excluded (based on a lack of data regarding 
CA125 levels, n=108) are described in Table 1. The geometric mean of the preoperative CA125 
concentration was 650 U/mL (95% CI 504–837 U/mL) and the median time from preoperative 
CA125 sampling to primary surgery was 15 days (range 0–34 days). The median time from 
surgery to postoperative serum CA125 measurement was 16 days (range 5–34 days) with a 
geometric mean of 197 U/mL (95% CI 159–243 U/mL).
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Epithelial ovarian cancer (n=498)
FIGO IIb-IV (n=377)
Primary surgery and
adjuvant chemotherapy (n=237)
FIGO I-IIa (n=121)
No surgery, neo adjuvant chemotherapy
or no chemotherapy (n=140)
Pre- and postoperative CA125
value available (n=187)
Outcome surgery available (n=181)
CA125 ≤5 weeks before surgery
CA125 ≤5 weeks after surgery
CA125 >35 U/mL
CA125 before chemotherapy (n=123)
Missing surgery report (n=6)
Missing CA125 values (n=50)
CA125 >5 weeks before surgery
CA125 >5 weeks after surgery
CA125 ≤35 U/mL
CA125 after chemotherapy (n=58)
Fig. 1. Flowchart describing the study sample selection.
1. Decline in serum CA125 levels and residual tumor volume after primary 
surgery
The majority of patients (92%) experienced a decline in serum CA125 levels after surgery. 
Only ten patients (8%) experienced a postoperative increase in CA125 levels. Comparisons 
across the three groups of surgery outcome showed that pre- and postoperative serum CA125 
levels were both significantly higher in the group of patients with an inadequate outcome 
of surgery. The height of the serum CA125 levels in the latter group were decreasing linearly 
across those with optimal and complete cytoreduction (p=0.034 and <0.001 for pre- and 
postoperative values, respectively) (Table 2, model 1). However, the absolute decline in serum 
CA125 levels was similar between the three groups (p=0.289) (Table 2, model 1). Indeed, the 
decline was greater in the inadequate outcome group than in the patients with an optimal or 
complete outcome (Fig. 2). Adjusting for potential confounders (Table 2, model 2) did not 
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Table 1. Characteristics of the study population
Variable Patients included (n=123) Patients excluded (n=108)* p-value†
Age (yr)‡ 61.3 (52.1-68.5) 61.4 (51.1-70.1) 0.950
Histology 0.030
Serous 83 (67.5%) 64 (59.3%)
Mucinous 9 (7.3%) 7 (6.5%)
Endometrioid 9 (7.3%) 10 (9.2%)
Clear cell 5 (4.1%) 6 (5.6%)
Adenocarcinoma NOS 13 (10.6%) 10 (9.2%)
Carcinosarcoma 3 (2.4%) 9 (0%)
Other 1 (0.8%) 11 (10.2%)
Tumor grade 0.280
1 7 (5.7%) 11 (10.2%)
2 26 (21.2%) 25 (23.1%)
3 65 (52.8%) 47 (43.5%)
Unknown 25 (20.3%) 25 (23.2%)
FIGO stage 0.050
II 10 (8.1%) 19 (17.6%)
III 89 (72.4%) 76 (70.4%)
IV 24 (19.5%) 13 (12.0%)
Ascites 0.010
None 34 (27.6%) 13 (12.0%)
0–1,000 mL 27 (22.0%) 35 (32.4%)
>1,000 mL 51 (41.5%) 45 (41.7%)
Unknown 11 (8.9%) 15 (13.9%)
Residual tumor size after debulking 0.320
Complete 33 (26.8%) 37 (34.2%)
Optimal 47 (38.2%) 42 (38.9%)
Suboptimal 43 (35.0%) 29 (26.9%)
Extensive surgery 0.030
Yes 48 (39.0%) 28 (25.9%)
No 75 (61.0%) 80 (74.1%)
CA125, U/mL
Preoperative 650 (504–837)
Postoperative 197 (159–243)
Perioperative decline 427 (310–588)
Follow-up time (mo)§ 31 (18–49)
FIGO, International Federation of Gynecology and Obstetrics.
*Excluded due to a lack of data regarding CA125 levels; †Unpaired t test (age) and χ2 test (other characteristics); ‡Mean (interquartile range); §Geometric means 
(95% confidence interval).
significantly alter these results. When relative declines in serum CA125 levels were cross-
tabulated with surgical outcome, a significant trend towards greater declines in those with a 
better surgical outcome was found (p=0.035) (Fig. 2).
2. Decline in serum CA125 levels and disease-specific survival
The median follow-up time was 31 months (range 0–178 months). During the course of 
follow-up 75 of the 123 patients died (68 of whom due to disease-specific causes). Kaplan-
Meier survival curves showed an increased mortality risk in patients with a lower relative 
decline in serum CA125 (p=0.002) (Fig. 3). Specifically, HR50%–79%=0.59 (95% CI: 0.34–1.05) 
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Table 2. Comparisons of levels of perioperative CA125 by category of surgery outcome
CA125 by category of 
surgery outcome
Descriptive Comparisons
CA125, in U/mL Loge CA125 Model 1 Model 2
Geometric mean 
(95% CI)
Mean (SD) ß 95% CI p-value ß 95% CI p-value
Preoperative
Inadequate (n=43) 908 (569–1,450) 6.81 (1.52) - - - - - -
Optimal (n=47) 610 (433–859) 6.41 (1.52) −0.40 −0.98, 0.18 0.181 −0.36 −0.93, 0.24 0.226
Complete (n=33) 460 (264–800) 6.13 (1.57) −0.68 −1.32, −0.04 0.037 −0.68 −1.31, −0.05 0.035
Linear trend 0.034 Linear trend 0.033
Postoperative
Inadequate (n=43) 341 (229–508) 5.83 (1.29) - - - - - -
Optimal (n=47) 170 (133–219) 5.14 (0.56) −0.70 −1.17, −0.24 0.003 −0.69 −1.16, −0.23 0.004
Complete (n=33) 118 (76–182) 4.76 (1.28) −1.06 −1.57, −0.55 <0.001 −1.06 −1.57, −0.55 <0.001
Linear trend <0.001 Linear trend <0.001
Decline (pre-postoperative)
Inadequate (n=43) 522 (283–508) 6.26 (1.89) - - - - - -
Optimal (n=47) 420 (271–650) 6.04 (1.44) −0.18 −0.91, 0.57 0.652 −0.17 −0.92, 0.58 0.654
Complete (n=33) 335 (166–678) 5.82 (1.88) −0.44 −1.26, 0.37 0.287 −0.44 −1.27, 0.39 0.301
Linear trend 0.289 Linear trend 0.303
Model 1, crude (i.e. unadjusted); Model 2, adjusted for potential confounders (i.e. patient’s age and time elapsed between preoperative CA125 assessment 
and surgery in comparisons of preoperative CA125; time between surgery and postoperative CA125 assessment in comparisons of postoperative CA125; both 
times in comparisons of perioperative decline in CA125). ß is the regression coefficient indicating the difference in preoperative CA125, postoperative CA125 and 
perioperative decline in (pre-post) CA125 in complete or optimal versus inadequate (referent) groups; note that because comparisons were performed on loge 
CA125 data the regression coefficient may need to be back transformed (by taking the anti-log of ß) for a more direct interpretation of the magnitude of the 
differences, which will then be expressed in percentage difference, i.e. (eß-1)*100; for instance, a ß of −0.40 indicates that the preoperative CA levels were 33% 
lower in the optimal vs. the inadequate groups.
SD, standard deviation; CI, confidence interval.
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Fig. 2. Decline in CA125 by categories of surgery outcome. (A) Absolute levels; (B) Relative levels (categorized and cross-tabulated).
and HR≥80%=0.35 (0.19–0.67) vs. the referent <50% (Table 3, model 1). Likewise, survival was 
linked to improved surgical outcome (HRoptimal=0.70 [0.41–1.20] and HRcomplete=0.35 [0.17–0.71] 
vs. the group of patients with an inadequate outcome of surgery [p=0.003]). Adjustments for 
age (Table 3, model 2) had no effect on these estimates. Multivariate Cox regression analysis, 
which included categories of serum CA125 decline and surgical outcome and also all other 
prognostic factors for survival as mentioned above as variables, identified only the decline 
in serum CA125 but not the outcome of surgery, as being significantly associated with better 
survival (HR50%–79%=0.52 [95% CI: 0.28–0.96] and HR≥80%=0.26 [95% CI: 0.13–0.54] vs. the 
serum CA125 decline of <50%; p<0.001) (Table 3, model 3). The same patterns of association 
were observed when reductions in CA125 levels were expressed on a continuous absolute scale 
rather than as categories of change in percentages (p=0.003) (Table 4).
DISCUSSION
The results reported suggest that perioperative changes in serum CA125 level is an 
early biomarker for predicting disease-specific survival in patients that have undergone 
cytoreductive surgery. After controlling for known prognostic factors, the relationship 
between changes in perioperative serum CA125 levels and disease-specific survival had 
greater prognostic value than the level of residual disease after primary surgery.
These findings are in agreement with those reported by others. Yoo et al. [6] reported that a 
≥75% decline in serum CA125 levels was an independent prognostic factor for progression-
free survival [11]. Zivanovic et al. [7] combined the decline of serum CA125 with the result of 
debulking surgery and showed that optimally debulked patients in the “high decline” group 
(≥80% reduction in CA125 levels) were at lower risk of recurrence than patients with a smaller 
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Fig. 3. Kaplan-Meier survival curves by categories of % perioperative decline in CA125.
decline. The multivariate analysis performed by Zivanovic et al. [7] also showed that disease-
specific survival had greater prognostic value than the level of residual disease after primary 
surgery, although they placed little emphasis on this in their report.
Our study confirmed the results of previous reports showing that the outcome of debulking 
surgery is correlated with disease specific survival [4,5]. Complete debulking surgery showed 
an improved disease specific survival when compared to inadequate debulking (HR=0.34, 
p=0.003). Although not significant, optimal debulking was also related to improved survival 
(HR=0.70, p=0.201) when compared to inadequate debulking. The fact that the latter was 
not significant is likely due to the small number of patients assessed in our study. When 
correlating the changes in perioperative CA125 levels and the outcome of surgery, we found 
a linear association between the categories of relative perioperative CA125 decline and the 
outcome of surgery (p=0.035). However, when comparing absolute levels of CA125 decline, 
this relationship was no longer apparent. The different results obtained when expressing 
changes in serum CA125 levels on a continuous scale or in relative terms can be explained by 
the fact that the latter values are inversely associated with the baseline values. In other words, 
for patients with higher baseline values, any absolute reduction in CA125 levels will always 
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Table 3. Determinants of disease specific mortality
Determinants Events/N Model 1 (unadjusted) Model 2 (age-adjusted) Model 3 (fully adjusted)
HR 95% CI p-value HR 95% CI p-value HR 95% CI p-value
Age (per 10 yr) - 1.04 0.83, 1.30 0.742 - - - 1.08 0.83, 1.40 0.568
Decline in CA125 <0.001
<50%* 30/41 1.00 - - 1.00 - - 1.00 - -
50%–79% 22/42 0.59 0.34, 1.05 0.071 0.58 0.33, 1.02 0.059 0.52 0.28, 0.96 0.036
≥80% 15/40 0.35 0.19, 0.67 0.001 0.34 0.18, 0.65 0.001 0.26 0.13, 0.54 0.001
Histology
Other 26/40 1.00 - - 1.00 - - 1.00 - -
Serous 41/83 0.62 0.37, 1.02 0.062 0.61 0.37, 1.02 0.061 0.46 0.26, 0.81 0.007
Tumor grade 0.687
1 or 2 19/33 1.00 - - 1.00 - - 1.00 - -
3 33/65 0.96 0.53, 1.75 0.896 0.94 0.52, 1.72 0.851 1.11 0.59, 2.08 0.810
Unknown 15/25 0.85 0.43, 1.69 0.644 0.81 0.40, 1.66 0.568 1.01 0.53, 1.94 0.972
FIGO
IV 17/24 1.00 - - 1.00 - - 1.00 - -
III 49/89 0.71 0.40, 1.26 0.240 0.71 0.40, 1.25 0.236 1.01 0.53, 1.94 0.972
II 1/10 0.09 0.01, 0.72 0.022 0.09 0.01, 0.72 0.023 0.17 0.02, 1.44 0.104
Ascites 0.710
None 16/34 1.00 - - 1.00 - - 1.00 - -
0–1,000 10/27 0.80 0.35, 1.80 0.586 0.80 0.35, 1.81 0.792 0.75 0.32, 1.77 0.509
>1,000 34/51 1.41 0.76, 2.60 0.277 1.41 0.76, 2.60 0.277 1.33 0.67, 2.64 0.413
Unknown 7/11 1.10 0.45, 2.70 0.747 1.10 0.45, 2.60 0.828 0.81 0.31, 2.15 0.675
Extensive surgery
No 41/75 1.00 - - 1.00 - - 1.00 - -
Yes 26/48 0.98 0.59, 1.62 0.927 0.98 0.59, 1.62 0.924 0.80 0.47, 1.38 0.427
Surgery outcome
Inadequate 30/43 1.00 - - 1.00 - - 1.00 - -
Optimal 26/47 0.70 0.41, 1.20 0.201 0.72 0.42, 1.23 0.225 0.81 0.44, 1.50 0.509
Complete 11/33 0.35 0.17, 0.71 0.003 0.34 0.17, 0.69 0.003 0.52 0.23, 1.22 0.133
Model 1, crude (i.e. unadjusted); Model 2, adjusted for age; Model 3, fully adjusted model (i.e. model 2 + all determinants considered).
HR, hazard ratio (vs. referent category as indicated by HR=1.00); CI, confidence interval; FIGO, International Federation of Gynecology and Obstetrics.
*Includes 10 patients in whom no changes or slight increases in CA125 were observed between pre- and postoperative.
be associated with a lower percentage reduction. Previous studies also showed a relationship 
between postoperative declines in serum CA125 levels and the level of residual disease 
after surgery. Rosen et al. [8] found that serum CA125 levels are related to the amount of 
remaining tumor tissue, and Brand and Lidor [9] and Gadducci et al. [11] reported a greater 
decline in postoperative CA125 levels in patients with small residual tumors than in those 
with bulky residual disease. Yedema et al. [10] also examined perioperative changes in serum 
CA125 levels, but reported the opposite result. The discord between these studies is most 
obviously explained by differences in the way in which serum CA125 levels were expressed: as 
absolute levels or in relative terms. Yedema et al. [10] expressed reductions in serum CA125 
levels on a continuous absolute scale. When we performed our analyses this way, we either 
did not found a relationship.
It is worth noting that three of the patients examined in this study showed an increase 
in CA125 levels after complete cytoreduction. Thus, we agree with Gadducci et al. [11] 
when they state that a reduction in antigen levels after surgery makes it difficult to predict 
the amount of residual disease with any accuracy. Nevertheless, we have to realize that 
intra-abdominal cytoreduction does not account for extra-abdominal tumor remnants. 
Furthermore, the group of patients with an optimal debulking includes patients with 1 
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Table 4. Determinants of disease specific mortality
Determinants Fully adjusted model
HR 95% CI p-value
Age (per 10 yr) 1.12 0.86, 1.46 0.410
Decline in CA125
Loge[CA125pre-post] 0.74 0.60, 0.90 0.003
Histology
Other 1.00 - -
Serous 0.50 0.29, 0.88 0.013
Tumor grade
1 or 2 1.00 - -
3 1.02 0.54, 1.96 0.940
Unknown 0.97 0.44, 2.14 0.932
FIGO
IV 1.00 - -
III 0.80 0.42, 1.54 0.504
II 0.12 0.01, 1.00 0.050
Ascites
None 1.00 - -
0–1,000 0.63 0.27, 1.50 0.301
>1,000 1.17 0.59, 2.30 0.652
Unknown 0.89 0.34, 2.33 0.815
Extensive surgery
No 1.00 - -
Yes 0.88 0.51, 1.52 0.655
Surgery outcome
Inadequate 1.00 - -
Optimal 0.72 0.40, 1.30 0.281
Complete 0.47 0.21, 1.05 0.066
Crude and age-adjusted values of HR (95% CI) for perioperative decline in CA125 were 0.91 (0.78, 1.06) and 0.82 
(0.66, 1.02), respectively; All analyses were conducted within hospital strata to account for the clustering of 
patients within hospitals (n=3).
HR, hazard ratio (vs. referent category as indicated by HR=1.00); CI, confidence interval; FIGO, International 
Federation of Gynecology and Obstetrics.
macroscopical tumor spot <1 cm as well as patients with 1,000 of these spots as is the case 
in some patients with peritoneal carcinomatosis. Finally, the surgeons’ intraoperative 
assessment of the amount of residual disease is subjective. Indeed, Préfontaine et al. [12] 
reported significant measurement errors and low inter-observer reliability. They concluded 
that most surgeons underestimated rather than overestimated the diameter of residual 
tumors. Chi et al. [13] and Lakhman et al. [14] identified tumors with a diameter greater 
than 1 cm on CT in almost half of patients deemed to have an optimal outcome after primary 
surgery. However, postoperative CT does not provide a truly objective assessment.
The present study has several limitations. The first is its retrospective nature. A second 
is that different assays were used to measure serum CA125 levels in the three hospitals. 
A third is that around 50% of the initial study population was excluded (n=108) due to a 
lack of data regarding CA125 levels. Some characteristics of these patients differ from the 
patients included that may be seen as a potential selection bias. The excluded patients 
had significantly more non-serous histology and less advanced stage disease. This could 
mean that our findings should be restricted to EOC (epithelial ovarian cancer) with serous 
histology and more advanced stage. A fourth is that serum CA125 levels were measured in 
different postoperative weeks (range 0–5 weeks), which may have influenced the rate of 
postoperative decline. However, we used a linear regression model to adjust for the potential 
confounding effects. Despite this, the fact that CA125 levels were measured at different times 
can still be regarded as a weakness. Indeed, the peritoneum normally forms a barrier to 
CA125 transport [15], and incision of the peritoneum leads to the release of CA125 into the 
peritoneal fluid. Thus, peritoneal trauma may cause CA125 release [16], and manipulation 
of the tumor during surgery may lead to increased shedding of CA125 into the circulation as 
remaining barriers between tumor and surrounding tissue are disturbed [17]. The removal 
of tumors and ascites from patients with ovarian cancer leads to a reduction in serum CA125 
levels, whereas peritoneal trauma caused by the surgical procedure does the opposite. 
Evidence suggests that postoperative CA125 levels increase after incision and healing of the 
peritoneum via de novo synthesis [18]. This increase may mask any decline in perioperative 
CA125 levels after the removal of tumor tissue and ultimately cause an increase in serum 
postoperative CA125 levels, as observed in ten of the patients examined in this study. Van 
der Zee et al. [19] examined the effect of abdominal surgery on serum CA125 levels by 
measuring postoperative levels in 84 patients with normal preoperative CA125 values (≤16 U/
mL) who had malignant and non-malignant disease. The highest level measured in patients 
who underwent aortic surgery was 215 U/mL (on postoperative day 7). The antigen levels 
in the entire study population increased from day 3, reaching a maximum on days 7 to 14 
before gradually declining to preoperative levels within 8 weeks. If performed prospectively, 
CA125 measurements should be done at regular intervals up until the start of chemotherapy, 
and values in different patients should be measured at the same time. In addition, a cutoff 
preoperative serum CA125 level should be defined and used as a criterion for inclusion in any 
study. In the present study, only ten patients (8%) showed a postoperative increase in CA125 
levels, eight of whom did have a preoperative serum CA125 level <200 U/mL.
In conclusion, the volume of residual tumor after debulking is known as the most important 
prognostic factor for survival, but it’s intraoperative assessment is rather subjective. We have 
identified a relationship between the perioperative relative change in CA125 levels and the 
amount of residual tumor remaining after primary cytoreductive surgery. Less residual tumor 
was associated with a greater relative decline in serum CA125 levels. Perioperative changes 
in serum CA125 levels were also associated with disease-specific survival and were a stronger 
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predictor than the estimated amount of cytoreduction at surgery. A decline of ≥80% resulted 
in an almost 4-fold increase in survival to all patients with advanced stage epithelial ovarian 
cancer who were treated with primary debulking surgery and adjuvant chemotherapy. If 
confirmed by prospective studies, the perioperative change in serum CA125 level in response 
to cytoreductive surgery enables predicting disease-specific survival more specific than the 
surgeons’ estimation of the residual tumor volume.
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